How FGF21 Works—the Hormone That Burns Fat

A Hormone Your Liver Makes—and Science Wants to Harness

Amid the global surge of interest in weight-loss drugs, a lesser-known hormone is drawing attention from researchers and pharmaceutical companies alike. FGF21—fibroblast growth factor 21—is a peptide hormone produced mainly by the liver that plays a surprisingly powerful role in regulating metabolism, sugar cravings, and body weight. Unlike the appetite-suppressing GLP-1 drugs that dominate headlines, FGF21 works through an entirely different mechanism: it ramps up the body's energy burning rather than simply reducing hunger.

What Is FGF21?

FGF21 belongs to the fibroblast growth factor family, a group of signalling molecules involved in cell growth and repair. But FGF21 is an oddity among its relatives. It does not stimulate cell division. Instead, it functions as an endocrine hormone—released into the bloodstream by the liver, pancreas, and fat tissue to regulate how the body processes energy, sugar, and fat.

Scientists sometimes call FGF21 a "master metabolic sensitizer" because it fine-tunes multiple hormonal signals at once, helping to restore energy balance when the body is stressed by fasting, overeating, or nutritional imbalance. It can cross the blood-brain barrier, giving it direct access to the brain circuits that govern appetite and metabolic rate.

How It Works in the Body

FGF21 exerts its effects by binding to a receptor complex made up of FGFR1 (a tyrosine kinase receptor) and a co-receptor called β-Klotho. This partnership is essential—without β-Klotho, FGF21 cannot signal effectively. The principal target tissues are the central nervous system, the liver, and adipose (fat) tissue.

Once activated, the downstream signalling cascades produce several metabolic effects:

• Increased energy expenditure—the body burns more calories, even at rest
• Enhanced insulin sensitivity—cells respond better to insulin, improving blood-sugar control
• Fat breakdown—FGF21 promotes lipolysis (the release of stored fat) and fatty-acid oxidation
• Reduced triglycerides—blood lipid levels drop as fat is processed more efficiently

The Sweet-Tooth Connection

One of FGF21's most surprising roles is its ability to suppress sugar cravings. Research published in Cell Metabolism showed that the liver releases FGF21 after sugar consumption, and the hormone then acts on hypothalamic neurons to reduce the desire for sweets—without affecting appetite for protein or complex carbohydrates.

A common genetic variant of the FGF21 gene (rs838133), carried by roughly 45 percent of people, is associated with a stronger "sweet tooth." People with this variant tend to consume more sugar, suggesting that natural differences in FGF21 signalling help explain why some individuals crave sweets far more than others.

A New Brain Circuit

A study published in Cell Reports by researchers at the University of Oklahoma identified the specific brain pathway through which FGF21 reverses obesity in mice. The hormone targets neurons in the nucleus of the solitary tract and the area postrema—two regions in the hindbrain—which then relay signals to the parabrachial nucleus. This circuit boosts metabolic rate rather than suppressing appetite, making FGF21's mechanism fundamentally different from that of GLP-1 receptor agonists.

From Lab Bench to Clinic

Pharmaceutical companies are already developing FGF21 analogues—engineered versions of the hormone with longer-lasting effects. Several are in advanced clinical trials for MASH (metabolic dysfunction-associated steatohepatitis), a severe form of fatty liver disease:

• Pegozafermin earned FDA Breakthrough Therapy designation after Phase 2 trials showed significant improvement in liver fibrosis and inflammation
• Efruxifermin demonstrated fibrosis reduction and MASH resolution in Phase 2 trials
• Efimosfermin achieved fibrosis improvement in over 45 percent of patients versus roughly 21 percent on placebo

While these drugs target liver disease first, researchers believe FGF21-based therapies could eventually complement existing weight-loss treatments by addressing metabolism from a different angle—burning more energy rather than eating less.

Why It Matters

FGF21 represents a fundamentally different approach to metabolic disease. Where current blockbuster drugs work primarily by curbing appetite, FGF21 tackles the other side of the energy equation—expenditure. If clinical trials continue to show promise, FGF21 analogues could offer a complementary or alternative option for the hundreds of millions of people worldwide living with obesity, fatty liver disease, and metabolic syndrome.